Yuan Defu, Liu Shanshan, Liu Yangyang, Ouyang Fei, Ai Wei, Shi Lingen, Liu Xiaoyan, Qiu Tao, Wang Bei, Zhou Ying
Department of Epidemiology and Health Statistics, Key Laboratory of Environmental Medicine Engineering of Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, China.
School of Public Health, Nanjing Medical University, Nanjing 211166, China.
Vaccines (Basel). 2023 Oct 19;11(10):1614. doi: 10.3390/vaccines11101614.
To understand the HPV infection profiles among Chinese HIV/AIDS patients and the HPV vaccine acceptance among unvaccinated Chinese people with different HIV infection statuses after the HPV vaccine launch in China, this study searched Web of Science, PubMed, Cochrane Library, Embase, Scopus, CNKI, WANFANG, SinoMed, and VIP databases up to 23 June 2023, according to the registered protocol (CRD42023449913). A total of 58 studies were included. The results showed that the HPV infection rate among Chinese HIV/AIDS patients was 52.54% (95% CI: 42.11-62.86%) and higher in males than in females (74.55% vs. 41.04%); meanwhile, the rate was higher in the anus than in the cervix (69.22% vs. 41.71%). Although there was no statistical difference, the high-risk HPV infection rate (38.98%) was higher than low-risk HPV (23.86%), and single infections were more common (28.84%) than multiple infections (19.23%). HPV vaccine acceptance among the unvaccinated Chinese population was 59.19% (95% CI: 52.50-65.89%), and was slightly higher among HIV-infected rather than non-HIV-infected individuals (67.72% vs. 59.58%). There was a difference in acceptance among respondents from different regions. Although the difference in acceptance rate between males and females was not statistically significant (61.10% vs. 61.18%), MSM had a higher acceptance rate than non-MSM (84.28% vs. 59.05%). HPV infection is prevalent among HIV patients, demonstrating the need to increase the frequency of HPV screening for PLWH. The HPV vaccine acceptance rate is higher than that of non-HIV-infected individuals. Male acceptance is almost the same as female's, with MSM acceptance higher than non-MSM, suggesting that using MSM, especially MSM in PLWH, as an entry point may be a practical avenue to explore to further expand the scope of HPV vaccination.
为了解中国艾滋病病毒/艾滋病（HIV/AIDS）患者中的人乳头瘤病毒（HPV）感染情况，以及在中国HPV疫苗上市后，不同HIV感染状态的未接种中国人对HPV疫苗的接受程度，本研究根据注册方案（CRD42023449913），检索了截至2023年6月23日的Web of Science、PubMed、Cochrane图书馆、Embase、Scopus、中国知网（CNKI）、万方、中国生物医学文献数据库（SinoMed）和维普数据库。共纳入58项研究。结果显示，中国HIV/AIDS患者的HPV感染率为52.54%（95%置信区间：42.11 - 62.86%），男性高于女性（74.55%对41.04%）；同时，肛门部位的感染率高于宫颈部位（69.22%对41.71%）。尽管无统计学差异，但高危型HPV感染率（38.98%）高于低危型HPV（23.86%），单一感染比多重感染更常见（28.84%对19.23%）。未接种HPV疫苗的中国人群中，HPV疫苗接受率为59.19%（95%置信区间：52.50 - 65.89%），HIV感染者的接受率略高于未感染HIV者（67.72%对59.58%）。不同地区的受访者在接受程度上存在差异。虽然男性和女性在接受率上的差异无统计学意义（61.10%对61.18%），但男男性行为者（MSM）的接受率高于非MSM（84.28%对59.05%）。HPV感染在HIV患者中普遍存在，这表明有必要增加对HIV感染者进行HPV筛查的频率。HPV疫苗接受率高于未感染HIV的个体。男性接受率与女性几乎相同，MSM的接受率高于非MSM，这表明以MSM，尤其是HIV感染者中的MSM为切入点，可能是进一步扩大HPV疫苗接种范围的一条切实可行的探索途径。
